Integrated product development is becoming an increasingly important strategy for successfully bringing a new drug to the market. It offers a path to the transformation of drug development by having various departments work collaboratively to devise a single integrated drug development strategy.
PharmaLex recently conducted a survey of 107 US respondents at director level and above across a wide range of pharmaceutical and biotechnology companies to understand where organizations are on their IPD journey. The webinar shares key insights from the survey and explores what these mean for industry.
Key learnings:
- Nearly half of the survey respondents have implemented an IPD program, while another 34% plan to in the next 12 months
- The number one objective for implementing an IPD program is to drive R&D innovation
- Without an IPD program, many companies continue to work in silos
